Abstract
Purpose :
To describe High Resolution Optical Coherence Tomography (HR-OCT) features in 33 cases of histologically confirmed Ocular Surface Squamous Neoplasia (OSSN), and to the correlation between them.
Methods :
Study Population: Patients were prospectively recruited at Cornea Department from March to October 2017, after Institutional Review Board approval and obtaining informed consent from all patients. Patients presenting with a suspicious conjunctival lesion that underwent incisional or excisional biopsy were recruited. Only patients with positive biopsies were included. HR-OCT: Spectral Domain HR-OCT with an approximate axial resolution of 5μm (RTVue, Optovue) was used for imaging tumors prior to incisional or excisional biopsy. Presence of classical findings of hyper-reflective, thickened epithelium and abrupt transition from normal to abnormal epithelium were recorded. Additionaly, tumor thickness was measured. Statistical Analysis: Data were entered into a standardized database. Statistical analysis was performed using SPSS 22.0.
Results :
Demographics of study population: 33 patients were included. Mean age of patients was 68.73 years (SD 15.67) and 57.6% (19) were male. Histological features: Biopsies were incisional in 69.7% (23) of patients. Pathology diagnosis was as follows: CIN I 36.4% (12), CIN II 33.3% (11), NIC III 24.2% and, Invasive carcinoma 6.1% (2). OCT features: Hyper-reflective epithelium and abrupt transition line was found in 100% of cases. Mean thickness of lesions was 271.21μm (SD 128.36, 115-633μm), being progressively higher as histological diagnosis was more severe: CIN I 206.66μm, CIN II 276.18μm, CIN III 325.75μm, Invasive carcinoma 413μm. A moderate correlation between tumor thickness and histological diagnosis was found (Spearman rho 0.547, p=0.001).
Conclusions :
As reported in previous studies, HR-OCT has a role as an adjunct tool in diagnosing ocular surface squamous neoplasia. Thickness of tumors by OCT may correlate with histological severity.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.